title: Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial.
abstract: The initial treatment of childhood-onset systemic lupus erythematosus (SLE) is not standardized. Although corticosteroids are the first-line therapy for SLE, long-term, high-dose steroid therapy is associated with various side effects in children. The Japanese Study Group for Renal Disease in Children (JSRDC) has carried out a multi-center, randomized, controlled trial to evaluate the efficacy and safety of corticosteroid and mizoribine (MZB) therapy as an initial treatment for newly diagnosed juvenile SLE. Twenty-eight patients were treated with a combination steroid and MZB (4-5 mg/kg/day) (group S+M) drug therapeutic regimen, while 29 patients were treated with steroid only (group S); both groups were followed up for 1 year. The time to the first flare from treatment initiation was not significantly different between the two groups (Kaplan-Meier method, p = 0.09). During the period when the steroid was given daily (day 0-183), the time to the first flare from treatment initiation was significantly longer in the patients of group S+M than in those of group S (log-rank test, p = 0.02). At the end of the study period, there were no differences in the severity of proteinuria and renal function impairment between the two groups. No patients dropped out of the trial due to adverse events. In conclusion, our combined steroid and MZB drug therapeutic regimen was not shown to be significantly better than the steroid-only therapy as initial treatment for juvenile SLE. Whether MZB administered in a higher dose would be therapeutically advantageous can only be answered by further studies.
authors.affiliation: Department of Pediatrics, Dokkyo Medical University Koshigaya Hospital, Koshigaya City, Saitama, Japan. yuriko@amy.hi-ho.ne.jp
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Norishige
authors.initials: N
authors.lastname: Yoshikawa
authors.forename: Shinzaburo
authors.initials: S
authors.lastname: Hattori
authors.forename: Satoshi
authors.initials: S
authors.lastname: Sasaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Ando
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ikeda
authors.forename: Masataka
authors.initials: M
authors.lastname: Honda
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000009:adverse effects; D017668:Age of Onset; D002648:Child; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007564:Japan; D053208:Kaplan-Meier Estimate; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008181:Lupus Nephritis / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000009:adverse effects; D011239:Prednisolone / Q000008:administration & dosage* / Q000009:adverse effects; D011507:Proteinuria / Q000188:drug therapy / Q000209:etiology; D020551:Pulse Therapy, Drug; D012008:Recurrence; D012263:Ribonucleosides / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D011239:Prednisolone; D008775:Methylprednisolone